We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
MedicalSystem

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Blood Test Could Screen for Changes in Proteins Prior to Breast Cancer Diagnosis

By LabMedica International staff writers
Posted on 23 Nov 2022
Print article
Image: A blood test for people with high risk of breast cancer could diagnose the disease at early stage (Photo courtesy of Pexels)
Image: A blood test for people with high risk of breast cancer could diagnose the disease at early stage (Photo courtesy of Pexels)

Researchers have found changes in the levels of particular proteins in people’s blood up to two years before they were diagnosed with breast cancer. The study could form the basis of blood testing for people with a genetic predisposition or a family history of breast cancer to ensure the disease is diagnosed early when the chances of survival are greatest.

The findings by researchers from Leiden University Medical Center (Leiden, The Netherlands) are from the Trial Early Serum Test Breast cancer (TESTBREAST) study. The study was initiated in 2011 and currently includes 1174 women who are at a high risk of breast cancer, due to their family history or because they carry gene variants that are known to raise their breast cancer risk. The women are being cared for at nine hospitals across The Netherlands where they are offered breast screening at a younger age and more regularly than the rest of the Dutch population who have an average risk of breast cancer. The study has been running for ten years and the women taking part have been giving blood samples at least once a year when they go for screening. Any who develop breast cancer also give samples at the time of diagnosis.

Researchers used a well-established technique called mass spectrometry to analyze the levels of different proteins in the women’s blood. They looked both for variation between different women and changes that emerge in individual women over time. So far, the researchers have made detailed analyses of 30 blood samples taken over time from three women who have been diagnosed with breast cancer and three women who have not developed breast cancer, and found distinct differences between the women over time. This has revealed a set of six proteins that were at higher or lower levels one to two years prior to diagnosis. The researchers will now validate their findings in a larger group of women with and without breast cancer taking part in the TESTBREAST study and in women taking part in other high-risk breast cancer research studies.

“These proteins could form the basis for a blood test for early detection of breast cancer in women at a higher risk. It’s important to note that we found more variation in the protein levels in the blood samples between women, compared to over time within the same woman who developed breast cancer. This shows that testing should probably be based both on proteins that differ between women with and without breast cancer and on proteins that alter in an individual person over time,” said Ms Sophie Hagenaars from Leiden University Medical Center. “If further research validates our findings, this testing could be used as an add-on to existing screening techniques. Blood tests are relatively simple and not particularly painful for most people, so people could be offered screening as often as needed.”

Related Links:
Leiden University Medical Center

New
Gold Supplier
Chemiluminescence Immunoassay Analyzer
MAGICL 6000
New
Microarray Hybridization Station
CapitalBio BioMixer II
New
Clinical Centrifuge
CAPPRondo
New
COVID-19 Test Cassette
NG TEST COVID Immuni-T

Print article
SUGENTECH INC.

Channels

Clinical Chem.

view channel
Image: Equivalence of Genetically Elevated LDL and Lipoprotein(a) on Myocardial Infarction (Photo courtesy of Viborg Regional Hospital)

Familial Hypercholesterolemia Patients With ACD Have Elevated Lipoprotein(a)

Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein (LDL cholesterol), in the blood and early cardiovascular... Read more

Microbiology

view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more

Pathology

view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more

Industry

view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.